Clinical trial · Observational
Preparatory Work to Assess Adherence to Oral Chemotherapy
Preparatory Work to Assess Adherence to Oral Chemotherapy Among Patients With Chronic Myeloid Leukemia
NCT02895542CI-TRIAL-00033251completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study to find out more about how patients take their anticancer medications and challenges related to taking cancer medications.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Oral Anti-Cancer Agent
- description
- No intervention
Primary outcomes (4)
- measure
- Patient Demographic and Health Behaviors Questionnaire
- timeFrame
- Study 1 day Visit
- description
- Questions will be asked about the participants demographic background and health behaviors.
- measure
- Brief Medication Questionnaire (BMQ)
- timeFrame
- Study 1 day Visit
- description
- A self-report tool for screening adherence and barriers to adherence. The tool includes a 5-item Regimen Screen that asks patients how they took each medication in the past week, a 2-item Belief Screen that asks about drug effects and bothersome features, and a 2-item Recall Screen about potential difficulties remembering.
- measure
- Single Item Adherence Measure 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is diagnosed with Chronic Myeloid Leukemia (CML) and is receiving care for CML at a participating CCDR NCORP practice, * Patient had been prescribed one of the following oral anticancer agents for CML for ≥30 days (Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib). Prior use of any of these medications is allowed, as long as they have been on a stable regimen for at least 30 days prior to enrollment. * Patient is 18 years of age or older Exclusion Criteria: * Patient does not speak English or requires an interpreter for medical visits * Patient is cognitively impaired, as determined by the referring provider
References
Publications (0)
Data not yet available
No reference posted for this study.